2018 China BioMed Innovation and Investment Conference (2018 CBIIC) will be held in Suzhou Industrial Park on September 18-20. Having drawn widespread international attention, the 2018 CBIIC English Website is online, to provide a better experience for the international participants. Participation registration, roadshow application and latest news are available now.

Time: September 18-20, 2018

Venue: Suzhou Jinji Lake International Convention Center

(Address: 688 East Suzhou Avenue, Suzhou Industrial Park, Suzhou, Jiangsu Province)

Hosts: 

China Pharmaceutical Innovation and Research Development Association (PhIRDA)

China Association for Medical Devices Industry (CAMDI)

Hong Kong Exchanges and Clearing Limited (HKEX)

Participants: 

700+ Research Institutions, Biotech’s, Pharmaceutical, and medical device companies

500+ Investment Institutions

3500+ Participants

CBIIC is an annual event for pharmaceutical enterprises and investment institutions, has been successfully held in 2016 and 2017. CBIIC has drawn more than 3500 participants, over 700 pharmaceutical industries and 500 investment institutions, including government officials, senior executives and experts in pharmaceutical industry and representatives from media. The 2018 CBIIC will broaden channels to improve the communication and cooperation among domestic and foreign pharmaceutical innovative enterprises.

International Roadshow

The 2018 CBIIC will have international roadshow sessions for US, Germany, UK, Australia and etc. This event is extensively drawing attention from pharmaceutical industry and investors all around the world, innovative projects from UK, Netherlands, Australia, Canada, Israel, Japan, Taiwan and Hong Kong are now preparing to apply roadshows. Hundreds of investments institutions will attend this event, participants could have more in-depth communication with investors. 2018 CBIIC will provide a network platform for pharmaceutical companies and investment institutions to integrate multi-resources from worldwide.

2 New Parallel Sessions

Artificial Intelligence Roadshow and Rare Disease and Orphan Drugs Roadshow, together with Opening Ceremony, Clinical Data Release, International Roadshows, Medical Devices Roadshows, Analysis on the Latest Pharmaceutical Policies Forum and Investors’ Experience Sharing Forum, more than 10 parallel sessions will be shown in this event.

HKEX has announced that pre-revenue biotech companies with certain market capitalization are allowed to be listed in Hong Kong since April 30, 2018, the biggest revolution for Hong Kong's capital market has come. The revolution will boost the innovations of life science, biotechnology, AI and Big Data and also create a great environment for the new economy and technology in the era of “Comprehensive Health”. Mr. Charles Li, Chief Executive Officer of HKEX Group, will participate in 2018 CBIIC to discuss that revolution and other hot issues of pharmaceutical innovation and capital market. The Springer Nature’s top academic journal, Nature, will continue to support this event and the Global Chief Editor of Nature Drug Discovery will join and share his opinions with us as well.

The 2018 CBIIC will provide a platform for the domestic pharmaceutical R&D enterprises to study the cutting-edge technology of international pharmaceutical innovation and explore the foreign market as well. For the financial institutions, 2018 CBIIC will provide them with an opportunity to draw capitals and seek the innovative products with more competitiveness. This event is also a great opportunity for those foreign enterprises and innovative products aiming to promote collaboration in China and financing from Chinese investors.

Bilingual simultaneous interpretation in Chinese and English will be provided during the whole conference.

Welcome to participate in the 2018 CBIIC and register in the English website for Roadshow Application and Participation.

For more information about 2018 CBIIC, please view here.

For the Instruction for the Registration and Roadshow Application, please view here.